1)岡崎美樹,片上信之,西尾千尋,他:進行肺癌症例に対する外来化学療法.癌と化療 28:1391-1395,2001
2)厚生労働省:特掲診療科の施設基準等及びその届け出に関する手続きの取り扱いについて.平成18年3月6日,保医発第0306003号.http://www.mhlw.go.jp/topics/2006/03/dl/tp0314-1b03.pdf
3)Hotta K, Matsuo K, Ueoka H, et al:Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:3852-3859, 2004
4)日本肺癌学会(編):EBMの手法による肺癌診療ガイドライン.2005年版.金原出版,2005
5)Yamamoto N, Nakagawa K, Uejima H, et al:Randomized phaseⅡ study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer. West Japan Thoracic Oncology Group(WJTOG)0104. Cancer 107:599-605, 2006
6)折田義正,下條文武,伊藤喜久,他:日本腎臓学会腎機能(GFR)・蛋白尿測定委員会報告書.日腎会誌 43:1-19,2001
7)Ando Y, Minami H, Saka H, et al:Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing. Br J Cancer 76:1067-1071, 1997
8)Kudoh S, Takeda K, Nakagawa K, et al:Phase Ⅲ study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer:results of the West Japan Thoracic Oncology Group Trial(WJTOG 9904). J Clin Oncol 24:3657-3663, 2006
9)Mukohara T, Takeda K, Miyazaki M, et al:Japanese experience with second-line chemotherapy with low-dose(60mg/m2)docetaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 48:356-360, 2001
10)Thatcher N, Chang A, Parikh P, et al:Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:results from a randomised, placebo-controlled, multicentre study(Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
11)Paez JG, Janne PA, Lee JC, et al:EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
12)Lynch TJ, Gell DW, Sordella R, et al:Activation mutations in the epicermal growth factor receptor underlysing responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2139-2199, 2004
13)Cappuzzo F, Hirsch FR, Rossi E, et al:Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Nathl Cancer Inst 97:643-655, 2005
14)イレッサ錠250プロスペクティブ調査(特別調査)に関する結果と考察.アストラゼネカ株式会社,2004
15)Ando M, Okamoto I, Yamamoto N, et al:Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24:2549-2556, 2006
16)厚生労働省:重篤副作用疾患別対応マニュアル,急性肺損傷・急性呼吸窮迫症候群.2006.http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1b09.pdf
17)Kato H, Ichinose Y, Ohta M, et al:A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721, 2004
18)Hamada C, Tanaka F, Ohta M, et al:Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23:4999-5006, 2005
19)Pignon J, Tribodet H, Scagliotti G, et al:Lung Adjuvant Cisplatin Evaluation(LACE):A pooled analysis of five randomized clinical trials including 4584 patients. 2006 ASCO Annual Meeting, Abstract No:7008, 2006
20)Winton T, Livingston R, Johnson D, et al:Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005
21)Douillard J, Rosell R, Lena M, et al:Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stageⅠB-ⅢA non-small-cell lung cancer(Adjuvant Navelbine International Trialist Association[ANITA]):a randomised controlled trial. Lancet Oncol 7:719-727, 2006
22)Ohe Y, Ohashi Y, Kubota K, et al:Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:Four-Arm Cooperative Study in Japan. Ann Oncol(doi:10. 1093/annonc/mdl377), 2006(印刷版に先立つ電子出版のみ)
23)Strauss G, Herndon J, Maddaus M, et al:Adjuvant chemothrapy in stageⅠB non-small cell lung cancer(NSCLC):Update of Cancer and Leukemia Group B(CALGB)protocol 9633, 2006 ASCO Annual Meeting, Abstract No:7007
24)NCCN Clinical Practice Guidelines in Oncology, Fever and Neutropenia, 2006. www.nccn.org
25)Kris M, Hesketh P, Somerfield M, et al:American Society of Clinical Oncology guideline for antiemetics in oncology:update 2006. J Clin Oncol 24:2932-2947, 2006
26)Smith T, Khatcheressian J, Lyman G, et al:2006 Update of recommendations for the use of white blood cell growth factors:An evidence-based clinical practice guideline. J Clin Oncol, 2006(印刷版に先立つ電子出版のみ)
27)Cullen M, Steven N, Billingham L, et al:Antibacterial prophylaxis after chemotherpay for solid tumors and lymphomas. N Engl J Med 353:988-998, 2005
28)吉田清一(監修):がん化学療法の有害反応対策ハンドブック.第4版.先端医学社,2004
29)Ando Y, Saka H, Ando M, et al:Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity:a pharmacogenetic analysis. Cancer Res 60:6921-6926, 2000
30)大腸癌・胃癌患者に対するグルクロン酸転移酵素(UGT1A1)遺伝子多形別塩酸イリノテカンの用量設定試験.https://center.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&recptno=R000000618&type=summary&language=J
31)石原和之,山本明史:抗がん剤の血管外漏出とその対策―特に皮膚障害について.改訂版.協和醗酵株式会社,2003.http://iyaku.kyowa.co.jp/anzen/images/koganzai.pdf
32)Semb K, Aamdal S, Qian P, et al:Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16:3426-3432, 1998
33)Mor V, Stalker M, Gralla R, et al:Day hospital as an alternative to inpatient care for cancer patients:a random assignment trial. J Clin Epidemiol 41:771-785, 1988
34)堀尾芳嗣,室 圭,朴 智栄,他:外来化学療法 安全で円滑な実施を目指した取り組み.肺癌 46:482,2006
35)Kubota K, Watanabe K, Kunitoh H, et al:Phase Ⅲ randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage Ⅳ non-small-cell lung cancer:the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22:254-261,2004